<unk>  is a human monoclonal IgG4 antibody that is FDA approved for the treatment of moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.   Common adverse reactions include injection site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, and dry eye.
Dupilumab
Nebacumab
Ustekinumab
Evolocumab
Burosumab
Sarilumab
Alirocumab
Guselkumab